BeOne Medicines (ONC) Liabilities and Shareholders Equity (2016 - 2025)
BeOne Medicines (ONC) has disclosed Liabilities and Shareholders Equity for 11 consecutive years, with $6.3 billion as the latest value for Q2 2025.
- On a quarterly basis, Liabilities and Shareholders Equity changed N/A to $6.3 billion in Q2 2025 year-over-year; TTM through Dec 2025 was $6.3 billion, a 45.65% decrease, with the full-year FY2024 number at $5.9 billion, up 22.93% from a year prior.
- Liabilities and Shareholders Equity was $6.3 billion for Q2 2025 at BeOne Medicines, up from $5.9 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $8.5 billion in Q4 2021 to a low of $4.8 billion in Q4 2023.
- A 5-year average of $6.1 billion and a median of $5.7 billion in 2023 define the central range for Liabilities and Shareholders Equity.
- Peak YoY movement for Liabilities and Shareholders Equity: surged 52.4% in 2021, then plummeted 35.78% in 2022.
- BeOne Medicines' Liabilities and Shareholders Equity stood at $8.5 billion in 2021, then plummeted by 35.78% to $5.5 billion in 2022, then dropped by 12.13% to $4.8 billion in 2023, then increased by 22.93% to $5.9 billion in 2024, then increased by 6.38% to $6.3 billion in 2025.
- Per Business Quant, the three most recent readings for ONC's Liabilities and Shareholders Equity are $6.3 billion (Q2 2025), $5.9 billion (Q4 2024), and $5.7 billion (Q1 2024).